Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

ge healthcare technologies inc. - GEHC

GEHC

Close Chg Chg %
82.00 0.44 0.54%

Closed Market

82.44

+0.44 (0.54%)

Volume: 5.93M

Last Updated:

Nov 22, 2024, 4:00 PM EDT

Trade Now

Company Overview: ge healthcare technologies inc. - GEHC

GEHC Key Data

Open

$81.96

 Day Range

80.56 - 82.57

52 Week Range

66.39 - 94.50

 Market Cap

$37.46B

Shares Outstanding

456.87M

 Public Float

442.47M

Beta

1.43

 Rev. Per Employee

N/A

P/E Ratio

22.46

 EPS

$3.67

Yield

14.63%

 Dividend

$0.03

EX-DIVIDEND DATE

Oct 18, 2024

 SHORT INTEREST

N/A

AVERAGE VOLUME

3.70M

  

GEHC Performance

1 Week
 
 0.29%
 
1 Month
 
 -7.26%
 
3 Months
 
 -3.28%
 
1 Year
 
 11.25%
 
5 Years
 
 N/A
 

GEHC Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 20
Full Ratings ➔

About ge healthcare technologies inc. - GEHC

GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. It operates through the following segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment, and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services, and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company’s history roots back to the year 1892 and it was incorporated on May 16, 2022 and is headquartered in Chicago, IL.

GEHC At a Glance

GE Healthcare Technologies, Inc.
500 West Monroe Street
Chicago, Illinois 60661
Phone 1-833-735-1139 Revenue 19.55B
Industry Medical Specialties Net Income 1.57B
Sector Health Technology 2023 Sales Growth 6.603%
Fiscal Year-end 12 / 2024 Employees 51,000
View SEC Filings

GEHC Valuation

P/E Current 22.458
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 25.569
Price to Sales Ratio 1.811
Price to Book Ratio 4.936
Price to Cash Flow Ratio 16.855
Enterprise Value to EBITDA 12.639
Enterprise Value to Sales 2.197
Total Debt to Enterprise Value 0.23

GEHC Efficiency

Revenue/Employee 383,372.549
Income Per Employee 30,745.098
Receivables Turnover 4.531
Total Asset Turnover 0.652

GEHC Liquidity

Current Ratio 1.003
Quick Ratio 0.785
Cash Ratio 0.279

GEHC Profitability

Gross Margin 40.691
Operating Margin 14.259
Pretax Margin 12.075
Net Margin 8.02
Return on Assets 5.241
Return on Equity 19.066
Return on Total Capital 9.249
Return on Invested Capital 9.315

GEHC Capital Structure

Total Debt to Total Equity 138.273
Total Debt to Total Capital 58.031
Total Debt to Total Assets 30.391
Long-Term Debt to Equity 122.627
Long-Term Debt to Total Capital 51.465
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Ge Healthcare Technologies Inc. - GEHC

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
17.16B 17.59B 18.34B 19.55B
Sales Growth
+3.19% +2.45% +4.30% +6.60%
Cost of Goods Sold (COGS) incl D&A
10.40B 10.41B 11.12B 11.60B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
630.00M 625.00M 633.00M 610.00M
Depreciation
222.00M 225.00M 228.00M 248.00M
Amortization of Intangibles
408.00M 400.00M 405.00M 362.00M
COGS Growth
+3.09% +0.13% +6.81% +4.28%
Gross Income
6.77B 7.17B 7.22B 7.96B
Gross Income Growth
+3.34% +6.01% +0.66% +10.18%
Gross Profit Margin
+39.43% +40.80% +39.37% +40.69%
2020 2021 2022 2023 5-year trend
SG&A Expense
4.05B 4.38B 4.66B 5.17B
Research & Development
810.00M 816.00M 1.03B 1.21B
Other SG&A
3.24B 3.56B 3.63B 3.96B
SGA Growth
-8.52% +8.20% +6.35% +10.97%
Other Operating Expense
- - - -
-
Unusual Expense
(5.00M) (62.00M) (16.00M) 297.00M
EBIT after Unusual Expense
2.73B 2.86B 2.58B 2.49B
Non Operating Income/Expense
51.00M 58.00M 18.00M 448.00M
Non-Operating Interest Income
- 49.00M 34.00M 26.00M
Equity in Earnings of Affiliates
7.00M 27.00M 13.00M 11.00M
Interest Expense
66.00M 40.00M 86.00M 578.00M
Interest Expense Growth
-25.00% -39.39% +115.00% +572.09%
Gross Interest Expense
66.00M 40.00M 86.00M 578.00M
Interest Capitalized
- - - -
-
Pretax Income
2.71B 2.88B 2.51B 2.36B
Pretax Income Growth
+29.60% +6.09% -12.63% -6.01%
Pretax Margin
+15.79% +16.35% +13.70% +12.08%
Income Tax
652.00M 600.00M 563.00M 743.00M
Income Tax - Current - Domestic
315.00M 196.00M 493.00M 213.00M
Income Tax - Current - Foreign
463.00M 422.00M 324.00M 345.00M
Income Tax - Deferred - Domestic
3.00M 83.00M (261.00M) 82.00M
Income Tax - Deferred - Foreign
(129.00M) (101.00M) 7.00M 103.00M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
7.00M 27.00M 13.00M 11.00M
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
2.06B 2.27B 1.95B 1.62B
Minority Interest Expense
51.00M 46.00M 51.00M 46.00M
Net Income
2.01B 2.23B 1.90B 1.57B
Net Income Growth
+21.49% +11.06% -14.85% -17.18%
Net Margin Growth
+11.69% +12.68% +10.35% +8.04%
Extraordinaries & Discontinued Operations
- - 18.00M (4.00M)
-
Discontinued Operations
- - 18.00M (4.00M)
-
Net Income After Extraordinaries
2.01B 2.23B 1.92B 1.57B
Preferred Dividends
- - - 183.00M
-
Net Income Available to Common
2.01B 2.23B 1.92B 1.39B
EPS (Basic)
4.4138 4.902 4.221 3.044
EPS (Basic) Growth
+31.69% +11.06% -13.89% -27.88%
Basic Shares Outstanding
454.71M 454.71M 453.93M 455.00M
EPS (Diluted)
4.4138 4.902 4.221 3.024
EPS (Diluted) Growth
+31.69% +11.06% -13.89% -28.36%
Diluted Shares Outstanding
454.71M 454.71M 453.93M 458.00M
EBITDA
3.35B 3.42B 3.20B 3.40B
EBITDA Growth
+20.37% +2.09% -6.52% +6.29%
EBITDA Margin
+19.52% +19.45% +17.43% +17.38%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 96.353
Number of Ratings 20 Current Quarters Estimate 1.264
FY Report Date 12 / 2024 Current Year's Estimate 4.297
Last Quarter’s Earnings 1.14 Median PE on CY Estimate N/A
Year Ago Earnings 3.93 Next Fiscal Year Estimate 4.681
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 14 10 17 18
Mean Estimate 1.26 0.98 4.30 4.68
High Estimates 1.30 1.01 4.34 4.88
Low Estimate 1.22 0.94 4.23 4.46
Coefficient of Variance 1.64 2.19 0.62 1.97

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 12 11 11
OVERWEIGHT 0 1 1
HOLD 7 7 7
UNDERWEIGHT 0 0 0
SELL 1 1 0
MEAN Overweight Overweight Overweight

Insider Actions for Ge Healthcare Technologies Inc. - GEHC

Date Name Shares Transaction Value
Aug 20, 2024 Roland Rott CEO, Imaging 24,983 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2024 Roland Rott CEO, Imaging 8,419 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2024 Adam Holton Chief People Officer 13,293 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2024 Philip D. Rackliffe CEO, Ultrasound & IGT 15,168 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2024 Adam Holton Chief People Officer 4,396 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2024 Philip D. Rackliffe CEO, Ultrasound & IGT 6,203 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2024 Adam Holton Chief People Officer 12,895 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2024 James K. Saccaro Chief Financial Officer 62,940 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $78 per share 4,909,320.00
May 30, 2024 Taha Kass-Hout Chief Technology Officer 67,300 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $78.7 per share 5,296,510.00
May 24, 2024 William Joseph Stromberg Director 7,432 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 William Joseph Stromberg Director 9,201 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 Catherine A. Lesjak Director 6,024 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 Risa J. Lavizzo-Mourey Director 7,065 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 Tomislav Mihaljevic Director 6,024 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 Rodney F. Hochman Director 7,238 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 Rodney F. Hochman Director 8,763 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 Phoebe L. Yang Director 6,024 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 Anne T. Madden Director 8,763 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 Anne T. Madden Director 7,238 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 H. Lawrence Culp Director 624,074 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Ge Healthcare Technologies Inc. in the News